St. Jude Medical Inc. (NYSE:STJ) wrapped up 2010 and put a bow on it with near-double-digit boosts to its top and bottom lines.
The St. Paul, Minn.-based medical device maker’s fourth-quarter profits rose 8.9 percent to $206.4 million, or 62 cents per diluted share, on sales of $1.35 billion during the three months ended Jan. 1. That compared with profits of $189.7 million, or 57 cents per diluted share, on sales of $1.20 billion during Q4 2009.
The numbers improve further once charges related to recent acquisitions are taken into account. Adjusted for acquisition costs from the buyouts of LightLab Imaging Inc. and AGA Medical, the settlement of a U.S. Justice Dept. probe, a charge on extra implantable cardiac defibrillator inventory and a tax benefit from a federal R&D credit, Q4 net income was $251.1 million, or 75 cents per adjusted, diluted share — up more than 17 percent over Q3 2009.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Chairman, president and CEO Daniel Stark said the company posted the strong results despite “difficult macro-economic challenges.”
Here’s a breakdown of how each STJ segment fared during the fourth quarter and 2010, compared with the same period in 2009:
| Q4 | % increase | 2010 | % increase | |
| Cardiac Rhythm Management | ||||
| ICDs | $458 million | 16% | $1.82 billion | 15% |
| Pacemakers | $304 million | flat | $708 million | 13% |
| TOTAL | $762 million | 9% | $3.04 billion | 10% |
| Cardiovascular | ||||
| Vascular closure | $92 million | -2% | $375 million | -2% |
| Heart valves | $87 million | 10% | $337 million | 4% |
| TOTAL | $287 million* | 20% | $1.04 billion | 9% |
| Atrial Fibrillation | $193 million | 13% | $708 million | 13% |
| Neuromodulation | $108 million | 15% | $380 million | 15% |
| *Includes a $25 million assist from AGA Medical. | ||||
St. Jude said it expects adjusted, consolidated Q1 net earnings in the range of 77 cents to 79 cents per; full-year adjusted, consolidated EPS are forecast to be between $3.25 and $3.30.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
STJ shares were down 2 percent to $41.76 in mid-morning activity.
Related articles
- St. Jude Medical says 3Q profits soar over 16 percent (medcitynews.com)
- St. Jude launches joint cardiac ultrasound system with Zonare (medcitynews.com)
- St. Jude Medical to acquire AGA Medical for $1.3 billion (medcitynews.com)
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
